Gastrointestinal Stromal Tumor – An Overview

Abstract

Gastrointestinal stromal tumors (GISTs) are rare tumors but are most common mesenchymal tumors of the digestive tract. They are commonly seen in the stomach (60%) and small intestine (30%). GISTs are likely derived from the interstitial cells of Cajal or their stem cell precursors. They are best characterized by computerized tomography and have a specific staining pattern on immunohistochemistry, i.e., C-Kit and DOG-1. The treatment of GIST is based on the risk assessment for relapse, and patients with localized GIST require resection with or without adjuvant imatinib mesylate (IM). Advanced unresectable tumors are usually treated with IM, with a number of further options available for patients post progression on IM. There is an increasing emphasis on identifying C-Kit and platelet-derived growth factor receptor alpha mutations in all patients with GIST, as these are driver mutations with current and future therapeutic implications.

Keywords

Gastrointestinal stromal tumor - Indian data - overview

Publication History

Received: 05 February 2020

Accepted: 10 April 2020

Article published online:
14 May 2021

• References

• 1 Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet 2013; 382: 973-83
• 2 Beham AW, Schaefer IM, Schüler P, Cameron S, Ghadimi BM. Gastrointestinal stromal tumors. Int J Colorectal Dis 2012; 27: 649-700
• 3 Lanke G, Lee JH. How best to manage gastrointestinal stromal tumor. World J Clin Oncol 2017; 8: 135-44
• 4 Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988; 335: 88-9
• 5 Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80
• 6 Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol 2016; 40: 39-46
• 7 Suresh Babu MC, Chaudhuri T, Babu KG, Lakshmaiah KC, Lokanatha D, Jacob LA. et al. Metastatic gastrointestinal stromal tumor: A regional cancer center experience of 44 cases. South Asian J Cancer 2017; 6: 118-21
• 8 Bose S, Ramaswamy A, Sahu A, Shetty O, Zanwar SS, Mirani J. et al. Clinical practice and outcomes in advanced gastrointestinal stromal tumor: Experience from an Indian tertiary care center. South Asian J Cancer 2017; 6: 110-2
• 9 Varshney VK, Gupta RK, Saluja SS, Tyagi I, Mishra PK, Batra VV. Analysis of clinicopathological and immunohistochemical parameters and correlation of outcomes in gastrointestinal stromal tumors. Indian J Cancer 2019; 56: 135-43
• 10 Lakshmi VA, Chacko RT, Kurian S. Gastrointestinal stromal tumors: A 7-year experience from a tertiary care hospital. Indian J Pathol Microbiol 2010; 53: 628-33
• 11 Rajappa S, Muppavarapu KM, Uppin S, Digumarti R. Gastrointestinal stromal tumors: A single institution experience of 50 cases. Indian J Gastroenterol 2007; 26: 225-9
• 12 Cyriac S, Rajendranath R, Sagar TG. Gastrointestinal stromal tumor: Analysis of outcome and correlation with c-kit status in Indian population. Indian J Cancer 2014; 51: 35-9
• 13 Ramaswamy A, Jain D, Sahu A, Ghosh J, Prasad P, Deodhar K. et al. Neoadjuvant imatinib: Longer the better, need to modify risk stratification for adjuvant imatinib. J Gastrointest Oncol 2016; 7: 624-31
• 14 Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R. et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-21
• 15 Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813-25
• 16 Martín J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero JA, García del MuroJ. et al Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: A study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005; 23: 6190-8
• 17 Ramaswamy A, Bal M, Swami R, Shetty O, Bose S, Pai T. et al. Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib. Ann Transl Med 2017; 5: 134
• 18 Patrikidou A, Domont J, Chabaud S, Ray-Coquard I, Coindre JM, Bui-Nguyen B. et al. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. Eur J Cancer 2016; 52: 173-80
• 19 Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW. et al. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 2017; 3: 944-52
• 20 Park CH, Kim EH, Jung DH, Chung H, Park JC, Shin SK. et al. Impact of periodic endoscopy on incidentally diagnosed gastric gastrointestinal stromal tumors: Findings in surgically resected and confirmed lesions. Ann Surg Oncol 2015; 22: 2933-9
• 21 Yamabe A, Irisawa A, Bhutani MS, Shibukawa G, Abe Y, Saito A. et al. Usefulness of endoscopic ultrasound-guided fine-needle aspiration with a forward-viewing and curved linear-array echoendoscope for small gastrointestinal subepithelial lesions. Endosc Int Open 2015; 3: E161-4
• 22 Imaging of Gastrointestinal Stromal Tumors: From Diagnosis to Evaluation of Therapeutic Response. Available from: http://ar.iiarjournals.org/content/36/6/2639.full. [Last accessed on 2018 Oct 16].
• 23 Imaging Therapy Response of Gastrointestinal Stromal Tumors (GIST) with FDG PET, CT and MRI: A Systematic Review SpringerLink. Available from: https://link.springer.com/article/10.1007/s40336-017-0229-8. [Last accessed on 2018 Oct 16].
• 24 Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008; 13 (Suppl. 02) 4-7
• 25 Laurini JA, Carter JE. Gastrointestinal stromal tumors: A review of the literature. Arch Pathol Lab Med 2010; 134: 134-41
• 26 Miettinen M, Lasota J. Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466-78
• 27 Hornick JL, Fletcher CD. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 2007; 38: 679-87
• 28 Charville GW, Longacre TA. Surgical Pathology of Gastrointestinal Stromal Tumors: Practical Implications of Morphologic and Molecular Heterogeneity for Precision Medicine. Adv Anat Pathol 2017; 24: 336-53
• 29 Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: A study of 1840 cases. Am J Surg Pathol 2009; 33: 1401-8
• 30 Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1 1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 2009; 33: 437-46
• 31 Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ. et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-65
• 32 Goh BK, Chow PK, Yap WM, Kesavan SM, Song IC, Paul PC. et al. Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol 2008; 15: 2153-63
• 33 Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411-9
• 34 Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83
• 35 Demetri GD, von MehrenM, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG. et al. NCCN Task Force report: Update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8 Suppl 2: S1-41
• 36 DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8
• 37 McCarter MD, Antonescu CR, Ballman KV, Maki RG, Pisters PW, Demetri GD. et al. Microscopically positive margins for primary gastrointestinal stromal tumors: Analysis of risk factors and tumor recurrence. J Am Coll Surg 2012; 215: 53-9
• 38 MacArthur KM, Baumann BC, Nicholl MB. Laparoscopic Versus Open Resection for Gastrointestinal Stromal Tumors (GISTs). J Gastrointest Cancer 2017; 48: 20-4
• 39 Hu J, Or BH, Hu K, Wang ML. Comparison of the post-operative outcomes and survival of laparoscopic versus open resections for gastric gastrointestinal stromal tumors: A multi-center prospective cohort study. Int J Surg 2016; 33 Pt A: 65-71
• 40 Nguyen SQ, Divino CM, Wang JL, Dikman SH. et al. Laparoscopic management of gastrointestinal stromal tumors. Surg Endosc 2006; 20: 713-6
• 41 Nakamori M, Iwahashi M, Nakamura M, Tabuse K, Mori K, Taniguchi K. et al. Laparoscopic resection for gastrointestinal stromal tumors of the stomach. Am J Surg 2008; 196: 425-9
• 42 Bischof DA, Kim Y, Dodson R, Carolina JimenezM, Behman R, Cocieru A. et al. Open versus minimally invasive resection of gastric GIST: A multi-institutional analysis of short- and long-term outcomes. Ann Surg Oncol 2014; 21: 2941-8
• 43 Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-6
• 44 Cameron S. Long-term adjuvant treatment of gastrointestinal stromal tumors (GIST) with imatinib-a comment and reflection on the PERSIST-5 study. Transl Gastroenterol Hepatol 2018; 3: 16
• 45 Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S. et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv68-iv78
• 46 DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M. et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg 2013; 258: 422-9
• 47 Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J. et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA 2012; 307: 1265-72
• 48 Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A. et al. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: An exploratory analysis of a randomized clinical trial. JAMA Oncol 2017; 3: 602-9
• 49 Raut CP, Espat NJ, Maki RG, Araujo DM, Williams TF, Wolff JE. et al. Extended treatment with adjuvant imatinib (IM) for patients (pts) with high-risk primary gastrointestinal stromal tumor (GIST): The PERSIST-5 study. J Clin Oncol 2017; 35 Suppl 15: 11009
• 50 Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P. et al. PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357-64
• 51 Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-9
• 52 Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD. et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26: 5360-7
• 53 Rutkowski P, Gronchi A, Hohenberger P, Bonvalot S, Schöffski P, Bonvalot S. et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): The EORTC STBSG experience. Ann Surg Oncol 2013; 20: 2937-43
• 54 Ramaswamy A, Ostwal V, Shetty O, Sahu A, Paul D, Pai T. et al. Neoadjuvant Imatinib in Locally Advanced Gastrointestinal stromal Tumours, Will Kit Mutation Analysis Be a Pathfinder?. J Gastrointest Cancer 2016; 47: 381-8
• 55 Hohenberger P, Langer C, Wendtner CM, Hohenberger W, Pustowka A, Wardelmann E. et al. Neoadjuvant treatment of locally advanced GIST: Results of APOLLON, a prospective, open label phase II study in KIT-or PDGFRA-positive tumors. J Clin Oncol 2012; 30 Suppl 15: 10031
• 56 Kurokawa Y, Yang HK, Cho H, Ryu MH, Masuzawa T, Park SR. et al. Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer 2017; 117: 25-32
• 57 Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients. J Clin Oncol 2010; 28: 1247-53
• 58 Dudeck O, Zeile M, Reichardt P, Pink D. Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib. Ann Oncol 2011; 22: 1828-33
• 59 Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer 2016; 19: 3-14
• 60 Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P. et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: The intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol 2009; 27: 3969-74
• 61 Yeh CN, Chen YY, Tseng JH, Chen JS, Chen TW, Tsai CY. et al. Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan. Transl Oncol 2011; 4: 328-35
• 62 Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA. et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-5
• 63 Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C. et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007; 25: 1107-13
• 64 Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F. et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: An open-label multicentre randomised phase 3 trial. Lancet Oncol 2010; 11: 942-9
• 65 Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Demetri MC. et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008; 216: 64-74
• 66 Oppelt PJ, Hirbe AC, Van Tine BA. Gastrointestinal stromal tumors (GISTs): Point mutations matter in management, a review. J Gastrointest Oncol 2017; 8: 466-73
• 67 Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P. et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006; 12: 2622-7
• 68 Yeh CN, Chen MH, Chen YY, Yang CY, Yen CC, Tzen CY. et al. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Oncotarget 2017; 8: 44121-30
• 69 Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006; 368: 1329-38
• 70 Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH. et al. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. J Clin Oncol 2017; 35: 1713-20
• 71 DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245: 347-52
• 72 Hasegawa J, Kanda T, Hirota S, Fukuda M, Nishitani A, Takahashi T. et al. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol 2007; 12: 212-7
• 73 Park SH, Ryu MH, Ryoo BY, Im SA, Kwon HC, Lee SS. et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: A phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs 2012; 30: 2377-83
• 74 Montemurro M, Cioffi A, Dômont J, Rutkowski P, Roth AD, von Moos R. et al. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). Cancer 2018; 124: 1449-54
• 75 Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E. et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): A randomised, multicentre, open-label phase 2 trial. Lancet Oncol 2016; 17: 632-41
• 76 Ramaswamy A, Pande N, Shetty O, Shetty N, Gupta S, Ostwal V. Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: Feasible and efficacious. J Gastrointest Oncol 2016; 7: 638-43
• 77 Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R. et al. Malignant gastrointestinal stromal tumors of the small intestine: A review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8: 50-9
• 78 Gatto L, Nannini M, Saponara M, Di Scioscio V, Beltramo G, Frezza GP. et al. Radiotherapy in the management of gist: State of the art and new potential scenarios. Clin Sarcoma Res 2017; 7: 4
• 79 Nishida T, Hirota S, Taniguchi M, Hashimoto K, Isozaki K, Nakamura H. et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998; 19: 323-4
• 80 Postow MA, Robson ME. Inherited gastrointestinal stromal tumor syndromes: Mutations, clinical features, and therapeutic implications. Clin Sarcoma Res 2012; 2: 16
• 81 Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E. et al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol 2012; 23: 353-60
• 82 Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT. et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-103
• 83 Cassier PA, Fumagalli E, Rutkowski P, Schöffski P, Van Glabbeke M, Debiec-Rychter M. et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012; 18: 4458-64
• 84 Farag S, Somaiah N, Choi H, Heeres B, Wang WL, van Boven H. et al. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. Eur J Cancer 2017; 76: 76-83
• 85 Heinrich MC, Jones RL, von Mehren M, Bauer S, Kang Y-K, Schoffski P. et al. Clinical activity of avapritinib in≥fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST). J Clin Oncol 2019; 37 Suppl 15: 110022
• 86 Survival Rates for Gastrointestinal Stromal Tumors. Available from: https://www.cancer.org/cancer/gastrointestinal-stromal-tumor/detection-diagnosis-staging/survival-rates.html. [Last accessed on 2018 Oct 24].